<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40939781</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-6280</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Current problems in cardiology</Title><ISOAbbreviation>Curr Probl Cardiol</ISOAbbreviation></Journal><ArticleTitle>Knowledge Mapping of SGLT2-Inhibitors and Cardiovascular Outcomes: A Bibliometric Analysis.</ArticleTitle><Pagination><StartPage>103171</StartPage><MedlinePgn>103171</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cpcardiol.2025.103171</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0146-2806(25)00191-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Initially developed for the treatment of type 2 diabetes mellitus (T2DM), SGLT2 inhibitors have increasingly been recognized for their substantial cardiovascular, renal, and metabolic benefits. This study undertakes a systematic bibliometric analysis to delineate research trends, quantify advancements, and identify influential studies on SGLT2 inhibitors and cardiovascular outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive literature search was performed using the Scopus database, resulting in 10,211 documents up to the search date. Both original research articles and reviews (narrative and systematic) were included. Quantitative metrics such as publication count, citation analysis, and authorship were employed. Network visualization tools (e.g., VOSviewer) and bibliometric software (R Studio with bibliometrix packages) were used to analyze collaboration networks, keyword co-occurrence, and thematic clustering.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The analysis revealed a significant upward trend in publication volume, with a notable peak in recent years, indicating a heightened interest in the topic among scientists. The United States and selected European institutions emerged as major contributors, with prominent authors and funding sources influencing the research output. Thematic analysis highlighted a focus on cardiovascular diseases, heart failure, renal outcomes, and mechanistic studies of SGLT2 inhibitor action. Notably, landmark randomized controlled trials have reported significant reductions in cardiovascular mortality, heart failure hospitalizations, and progression of kidney disease.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study underscores the transformative impact of SGLT2 inhibitors on cardiovascular therapy. The analytical framework highlights the expansion of the field, and the integration of translational research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rezabakhsh</LastName><ForeName>Aysa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: rezabakhsha@tbzmed.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iraji</LastName><ForeName>Hadis</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avagimyan</LastName><ForeName>Ashot</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghajanova</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jndoyan</LastName><ForeName>Zinaida</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirzoyan</LastName><ForeName>Lilia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Tambov State University after G. R. Derzhavin, Tambov, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Waseem</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Chemical Sciences, University of Peshawar, Pakhtunkhwa, Pakistan. Electronic address: Waseem_anw@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habtemariam</LastName><ForeName>Solomon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pharmacognosy Research &amp; Herbal Analysis Services, University of Greenwich, Kent, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meddahi-Pell&#xe9;</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory for Vascular Translational Science, Nanotechnologies for Vascular Medicine and Imaging, University Sorbonne Paris Nord, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavon-Djavid</LastName><ForeName>Graciela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departement of Hygiene, Security Environment, University Sorbonne Paris Nord, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barzegri</LastName><ForeName>Abolfazl</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Probl Cardiol</MedlineTA><NlmUniqueID>7701802</NlmUniqueID><ISSNLinking>0146-2806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bibliometric analysis</Keyword><Keyword MajorTopicYN="N">Cardiovascular Disease</Keyword><Keyword MajorTopicYN="N">Heart Failure</Keyword><Keyword MajorTopicYN="N">Sodium-glucose co-transporter-2 Inhibitor</Keyword></KeywordList><CoiStatement>Declaration of competing interest All accepted articles will be published only after the signed disclosure statements have been completed. 1. Did the authors of the manuscript receive funding, grants, or in-kind support in support of the research or the preparation of the manuscript? NO 2 Did the author have association or financial involvement (i.e. consultancies/advisory board, stock ownerships/options, equity interest, patents received or pending, royalties/honorary) with any organization or commercial entity having a financial interest in or financial conflict with the subject matter or research presented in the manuscript? NO</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>13</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>13</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40939781</ArticleId><ArticleId IdType="doi">10.1016/j.cpcardiol.2025.103171</ArticleId><ArticleId IdType="pii">S0146-2806(25)00191-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>